Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for an approved new animal drug application (NADA) from Alpharma Inc., to Pharmaq AS. The drug labeler code for Pharmaq AS is also being listed.

DATES:

This rule is effective September 2, 2005.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: david.newkirk@fda.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Alpharma Inc., One Executive Drive, Fort Lee, NJ 07024, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 125-933 for ROMET-30 (sulfadimethoxine/ormetoprim) Type A medicated article to Pharmaq AS, Skogmo Industriomrade, N-7863 Overhalla, Norway. Accordingly, the agency is amending the regulations in 21 CFR 558.575 to reflect the transfer of ownership.

In addition, Pharmaq AS has not been previously listed in the animal drug regulations as a sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to add entries for Pharmaq AS.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Section 510.60o is amended in the table in paragraph (c)(1) by alphabetically adding a new entry for “Pharmaq AS” and in the table in paragraph (c)(2) by numerically adding a new entry for “015331” to read as follows:

End Amendment Part
Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(1) * * *

Firm name and addressDrug labeler code
*    *    *    *    *
Pharmaq AS, Skogmo Industriomrade, N-7863 Overhalla, Norway.015331
*    *    *    *    *
Start Printed Page 52292

(2) * * *

Drug labeler codeFirm name and address
*    *    *    *    *
015331Pharmaq AS, Skogmo Industriomrade, N-7863 Overhalla, Norway.
*    *    *    *    *
Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

4. Section 558.575 is amended in paragraph (a)(2) by removing “046573” and by adding in its place “No. 015331”.

End Amendment Part Start Signature

Dated: August 22, 2005.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 05-17472 Filed 9-1-05; 8:45 am]

BILLING CODE 4160-01-S